109 related articles for article (PubMed ID: 1957836)
21. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of topotecan for pediatric patients with malignant solid tumors.
Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
Langevin AM; Casto DT; Thomas PJ; Weitman SD; Kretschmar C; Grier H; Pratt C; Dubowy R; Bernstein M; Blaney S; Vietti T
J Clin Oncol; 1998 Jul; 16(7):2494-9. PubMed ID: 9667269
[TBL] [Abstract][Full Text] [Related]
24. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
25. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
26. Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
Bibby MC; Double JA; Loadman PM
Br J Cancer; 1988 Sep; 58(3):341-4. PubMed ID: 3179187
[TBL] [Abstract][Full Text] [Related]
27. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
29. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
31. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.
Relling MV; Evans RR; Groom S; Crom WR; Pratt CB
J Pharmacokinet Biopharm; 1993 Dec; 21(6):639-51. PubMed ID: 8138891
[TBL] [Abstract][Full Text] [Related]
32. In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015).
Schroyens WA; Dodion PF; Sanders C; Loos M; Dethier NE; Delforge AR; Stryckmans PA; Kenis Y
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1135-9. PubMed ID: 3653209
[TBL] [Abstract][Full Text] [Related]
33. Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ; Shoemaker D; Zaharko DS; Grieshaber C; Plowman J; Corbett T; Valeriote F; King SA; Cradock J; Hoth DF
Cancer Chemother Pharmacol; 1987; 19(1):6-10. PubMed ID: 3545524
[TBL] [Abstract][Full Text] [Related]
34. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
Bailey H; Tutsch KD; Arzoomanian RZ; Tombes MB; Alberti D; Bruggink J; Wilding G
Cancer Res; 1991 Feb; 51(4):1105-8. PubMed ID: 1705165
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
36. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
37. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
38. Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
Futami H; Hornung RL; Back TT; Bull R; Gruys E; Wiltrout RH
Cancer Res; 1990 Dec; 50(24):7926-31. PubMed ID: 2253233
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
40. Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).
Pratesi G; Manzotti C; Damia G; D'Incalci M
Br J Cancer; 1988 Aug; 58(2):144-6. PubMed ID: 3166904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
